Search by Drug Name or NDC
NDC 00074-2625-84 Mavyret 100; 40 mg/1; mg/1 Details
Mavyret 100; 40 mg/1; mg/1
Mavyret is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is GLECAPREVIR; PIBRENTASVIR.
MedlinePlus Drug Summary
The combination of glecaprevir and pibrentasvir is used to treat certain types of chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in adults and children 3 years of age and older. It is also used to treat certain types of chronic hepatitis C infection in adults and children 3 years of age and older who have already received another medication to treat their hepatitis C infection. Glecaprevir is in a class of medications called HCV NS3/4A protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Pibrentasvir is in a class of medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C to spread inside the body.
Related Packages: 00074-2625-84Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Glecaprevir and Pibrentasvir
Product Information
| NDC | 00074-2625 |
|---|---|
| Product ID | 0074-2625_085d0018-b2f0-4da6-b528-a2866430599c |
| Associated GPIs | 12359902350320 |
| GCN Sequence Number | 077637 |
| GCN Sequence Number Description | glecaprevir/pibrentasvir TABLET 100MG-40MG ORAL |
| HIC3 | W0E |
| HIC3 Description | HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMB |
| GCN | 43699 |
| HICL Sequence Number | 044453 |
| HICL Sequence Number Description | GLECAPREVIR/PIBRENTASVIR |
| Brand/Generic | Brand |
| Proprietary Name | Mavyret |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Glecaprevir and Pibrentasvir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 100; 40 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | GLECAPREVIR; PIBRENTASVIR |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209394 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00074-2625-84 (00074262584)
| NDC Package Code | 0074-2625-84 |
|---|---|
| Billing NDC | 00074262584 |
| Package | 84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84) |
| Marketing Start Date | 2021-06-22 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 152.564 |
| Pricing Unit | EA |
| Effective Date | 2023-07-19 |
| NDC Description | MAVYRET 100-40 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |